Modern topical treatment of psoriasis in diabetic patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Psoriasis is a chronic inflammatory, immune-mediated skin disease that affects 2-3% of the population worldwide. Psoriasis is often associated with metabolic diseases such as diabetes mellitus, obesity, dyslipidemia, metabolic syndrome and non-alcoholic fatty liver disease. The presence of concomitant diseases is of great importance in the choice of therapy for patients with psoriasis. On the one hand, the rational therapy of psoriasis should stop the exacerbations quickly enough, and on the other, maintain the duration of remission. Some drugs used for the treatment of psoriasis, however, can adversely affect concomitant diseases, determining a more careful selection of therapy for such patients. The article discusses modern methods of topical therapy for psoriasis and describes the clinical experience with the use of Kartalin cream in patients with psoriasis occurring against a background of metabolic disorders.

Full Text

Restricted Access

About the authors

S. G Lykova

Novosibirsk State Medical University

Department of Dermatovenereology and Cosmetology

O. B Nemchaninova

Novosibirsk State Medical University

Department of Dermatovenereology and Cosmetology

Elena V. Svechnikova

Novosibirsk State Medical University

Email: elene-elene@bk.ru
Dr. Sci. (Med.), Associate Professor, Professor at the Department of Dermatovenerology and Cosmetology

M. A Morzhanayeva

Novosibirsk State Medical University

Department of Dermatovenereology and Cosmetology

References

  1. Данилов С.И., Нечаева О.С., Пирятинская А.Б. Медико-социальные факторы риска обострений хронических дерматозов. Российский журнал кожно-венерологических болезней. 2006;1:60-6.
  2. Walter J.F., Stoughton R.B., DeQuoy PR. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. Br J. Dermatol. 1978;99:89-96. Doi: 10.1111/ j.1365-2133.1978.tb01965.x.
  3. Gerritsen M.J., Rulo H.F., Van Vlijmen-Willems I., et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biologic study. Br J. Dermatol. 1993;128:666-73. doi: 10.1111/j.1365-2133.1993.tb00263.x.
  4. Reichtrath J., Perez A., Muller S.M., et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. (Stockh).1997;77:268-72. doi: 10.2340/00015555 772 682 72
  5. Lebwohl M., Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-502. Doi: 10.1067/ mjd.2001.117046
  6. Duvic M., Nagpal S., Asano A.T., Chandraratna R.A. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37:18-24
  7. Weinstein G.D., Krueger G.G., Lowe N.J., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85-92. Doi: 10.1016/ s0190-9622(97)70216-0.
  8. Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15. doi: 10.1016/j.jaad.2005.01.010
  9. Dahl M.G.C. Hazards of topical steroid therapy. Adv Drug React Bull. 1985;115:428-31.
  10. Ammar N.M., Rao B., Schwartz R.A., Janniger C.K. Adolescent striae. Cutis. 2000;65:69-70.
  11. Lebwohl M.G., Tan M.H., Meador S.L., Singer G. Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44:77-82. Doi: 10.1067/ mjd.2001.110046.
  12. Ramsay B., Lawrence C.M., Bruce J.M., Shuster S. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 1990;23:73-6. doi: 10.1016/0190-9622(90)70189-o.
  13. Runne U., Kunze J. Short duration ("minutes") therapy with dithranol for psoriasis: a new outpatient regimen. Br J Dermatol. 1982;106:135-39. doi: 10.1111/j.1365-2133.1982.tb00922.x.
  14. Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10:7-12. doi: 10.2165/0128071-200910001-00002.
  15. Witman P.M. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943-49. doi: 10.4065/76.9.943.
  16. Bruner C.R., Feldman S.R., Ventrapragada M., Fleischer A.B. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol On-line J. 2003;9:2.
  17. Lebwohl M.G., Breneman D.L., Goffe B.S. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am Acad Dermatol. 1998;39:590-96.Doi: 10.1016/ s0190-9622(98)70008-8.
  18. lebwohl M., Lombardi K., Tan M.H. Duration of improvement of psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0,05% ointment: comparison of maintenance treatments. Int J. Dermatol. 2001;40:64-6. doi: 10.1046/j.1365-4362.2001.01067-7.x.
  19. Kaidbey K., Kopper S.C., Sefton J., Gibson J.R. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J. Dermatol. 2001;40:468-71. doi: 10.1046/j.1365-4362.2001.01234.x.
  20. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J. Dermatol. 1999;38:16-24. doi: 10.1046/j.1365-4362.1999.00500.x.
  21. Дмитрук В.С. Опыт применения мази Карталин при ладонно-подошвенной форме псориаза идругих кератодермиях. Бюллетень сибирской медицины. 2011;1:112-16
  22. Солятова В.М. Оптимизация терапии псориаза с учетом изменений липидной плен ки в окологодовом ритме. Дисс. канд. мед. наук. Новосибирск, 2009

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies